UC Irvine

The development of nanobody research holds the potential to revolutionize targeted therapies. This study focuses on nanoparticles functionalized with recombinant Anti-HER2 nanobodies to specifically bind to cancer cells that overexpress HER2 receptors. Utilizing the high affinity and specificity of nanobodies, these nanoparticles are optimized to serve as precise tools for recognizing and adhering to cancer cells. This method not only facilitates the direct delivery of drugs to tumor sites but also minimizes damage to healthy tissues. This method involves constructing recombinant proteins with the 2Rb17c HER2 nanobody in the pRS-4420 vector and expressing the proteins in Saccharomyces cerevisiae. The recombinant nanobody proteins were successfully conjugated to nanoparticles. This study demonstrates the potential for future applications in targeting HER2-positive cells, offering promising prospects for enhanced binding efficacy in targeted therapies.